
Study Period | 2019 - 2030 |
Market Size (2025) | USD 16.08 Billion |
Market Size (2030) | USD 21.71 Billion |
CAGR (2025 - 2030) | 6.20 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Low |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Veterinary Biologics Market Analysis
The Veterinary Biologics Market size is estimated at USD 16.08 billion in 2025, and is expected to reach USD 21.71 billion by 2030, at a CAGR of 6.20% during the forecast period (2025-2030).
Rising demand for veterinary biologics, driven by the need to manage infectious diseases and advancements in genomics, is fueling market growth. Additionally, the increasing adoption of regenerative medicine is further supporting this expansion. Companies in the market are implementing strategies to strengthen their presence in developing economies and leverage untapped opportunities in these regions. Companies are pouring investments into state-of-the-art technologies, aiming to boost product performance, reliability, and overall user experience. Such advancements not only draw in new clientele but also ensure the loyalty of current customers by adapting to their changing needs.
Advancements in genomics is a driving factor for veterinary biologics market. As of June 2023, Researchers acknowledged two pivotal advancements in gene editing which included regulatory approval for pork derived from gene-edited pigs to enter the human food supply and the development of a calf with enhanced resistance to bovine viral diarrhea virus (BVDV). The Food and Drug Administration (FDA) announced a strategic collaboration with the National Institute of Standards and Technology (NIST) to develop a comprehensive resource aimed at supporting organizations innovating in animal biotechnology, particularly through the application of gene editing to modify animal genomes. Such advancements provide breakthrough solutions for animal health, in turn driving the demand for veterinary biologics market.
Globally, the rise in animal-related infectious diseases is contributing to the growth of the veterinary biologics market. The U.S. Centers For Disease Control and Prevention (CDC) reported in March 2023 that over 60% of known infectious diseases in humans originate from animals, and 75% of newly emerging diseases also have animal origins. This highlights the CDC's ongoing efforts to address zoonotic diseases in the United States and globally. The growing prevalence of infectious diseases, such as avian flu, further drives the market. As of December 2024, the H5N1 avian flu, which initially emerged in Europe in 2020, has significantly impacted wildlife and livestock, affecting over 10,000 wild birds, 125 million poultry, and 875 dairy herds across various states. The virus has also impacted 485 bird species and 48 mammal species, causing fatalities among diverse animals, including seals, dolphins, bald eagles, and even a zoo tiger. These developments are expected to boost the veterinary biologics market further.
The rising demand for regenerative medicine is also a key factor driving the veterinary biologics market. Regenerative medicine in animal health involves therapies to repair, replace, or regenerate damaged tissues and organs. These therapies are also used to address chronic conditions such as arthritis, sprains, and other injuries. A critical component of veterinary regenerative medicine is mesenchymal stromal cells (MSCs), part of the body's repair system. Research published by the National Institutes of Health (NIH), in March 2022, demonstrated the successful application of autologous MSCs in dogs and rabbits for treating chondral defects and promoting bone regeneration. Porcine and equine are emerging as promising models for further studies, which are expected to support market growth.
However, the market faces critical challenges due to the stringent regulations imposed by the government.
Veterinary Biologics Market Trends
Vaccine Segment Held the Largest Share in Veterinary Biolobics Market During Forecast Period
Veterinary vaccines safeguard animal and human health, minimize animal suffering, and ensure sustainable food production. These vaccines include those for rabies, west nile virus, and RNA-based solutions. The rising prevalence of rabies among animals, combined with government-driven vaccination initiatives, has significantly increased the demand for vaccines such as adjuvant and recombinant vaccines.
West Nile virus (WNV) affects various animals, including horses, birds, and some mammals. The National Institutes of Health (NIH) reported in February 2023 that in South Africa, 93.7% of horses testing positive for WNV displayed neurological symptoms, and 34.2% did not survive. Studies have also shown a seroprevalence rate of 53.9% in horses. Licensed vaccines available for WNV in animals include West Nile Innovator, Vetera, Recombiteck Equine West Nile Virus Vaccine, and ChimeriVax-WN0. These vaccines are given intramuscularly and require an initial series of injections followed by yearly boosters. Horses with weakened immune systems may need more frequent doses. This trend is likely to support the growth of the vaccines segment in the near future.
Additionally, global vaccination programs are playing a key role in market expansion. As of January 2023, two vaccine banks managed by the World Organization for Animal Health (WOAH) were operational, focusing on rabies and peste des petits ruminants (PPR). The WOAH World Fund has extensive experience in managing vaccine banks and facilitating vaccinations for diseases such as avian influenza (AI), foot-and-mouth disease (FMD), rabies, and PPR. These efforts have been supported by funding from various countries and organizations, including Australia, Canada, China, the European Union, France, Germany, Japan, New Zealand, the World Bank, and the Bill & Melinda Gates Foundation. Recognizing WOAH's effectiveness in vaccine procurement, WHO has sourced all its dog rabies vaccine orders through the WOAH Rabies Vaccine Bank since 2014. This collaboration enabled WHO to deliver 16.3 million rabies vaccine doses by January 2023. Such vaccine delivery has kept the animals free from diseases such as rabies, driving the overall market growth.
Due to vaccination for West Nile virus and global vaccination programs initiated by governments, the vaccine segment holds a significant share in 2024 and is projected to maintain its leading position during the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period
North America emerged as the frontrunner in the veterinary biologics market, driven by a surge in investments from pet owners prioritizing preventive care and bolstered by an enhanced veterinary healthcare infrastructure.
In the U.S., pet owners increasingly turn to preventive measures, like vaccinations, underscoring their commitment to pet well-being. Core dog vaccines encompass rabies, distemper, adenovirus, parvovirus, and parainfluenza. Highlighting the urgency, Rabies Watch reported 3,579 rabies cases in U.S. animals as of March 2022, marking a 2.3% dip from 2021's 3,663 cases. This dip is mainly due to the veterinary vaccines introduced in the United States. For instance, in September 2024, the USDA granted approval for the NOBIVAC NXT Feline Leukemia Virus (FeLV) vaccine. Set to hit veterinary clinics and hospitals across the nation this fall, the vaccine employs RNA-particle technology, safeguarding cats against prevalent infectious diseases. Such factors are set to amplify the demand for veterinary biologics, propelling North America's market growth.
In Canada, a surge in canine parvovirus (CPV) cases has heightened the demand for veterinary biologics such as veterinary vaccines. Canada identifies three main CPV variants: CPV-2b, CPV-2c, and CPV-2a. The National Institutes of Health (NIH) noted that, as of December 2022, CPV-2b dominated, with an 89.8% prevalence across seven provinces. In contrast, CPV-2c held a mere 2% prevalence, while CPV-2a was spotted in Alberta, British Columbia, and Quebec at 8.2%. Such troubling CPV statistics bolster the demand for veterinary biologics, driving market growth in Canada and the broader North American region.
The U.S. boasts an enhanced veterinary healthcare infrastructure, further fueling the veterinary biologics market. Mars Inc., a key player, is the largest operator of standalone veterinary clinics in the U.S., boasting over 2,000 practices under the Banfield, VCA, and BluePearl banners. Additionally, Otto.vet reported in November 2023 that the U.S. is home to approximately 126,138 practicing veterinarians, with 75,349 engaged in private practice. Thus, the rising number of veterinarians and company’s expansion of outreach by serving the veterinary clinics collectively bolster the market's expansion.

Veterinary Biologics Industry Overview
The veterinary biologics market is fragmented due to the presence of several manufacturers operating globally and regionally. Some of the leading players in the market are Boehringer Ingelheim, Ceva, Elanco Animal Health, Hester Biosciences Limited, and Meiji Animal Health Co., Ltd, amongst others.
Veterinary Biologics Market Leaders
-
Boehringer Ingelheim
-
Ceva
-
Elanco Animal Health
-
Hester Biosciences Limited
-
Meiji Animal Health Co., Ltd
- *Disclaimer: Major Players sorted in no particular order

Veterinary Biologics Market News
- October 2024: Vetlen Advanced Veterinary Devices unveiled its latest innovation which is a device designed to administer antibiotic medication straight to infected surgical and wound sites in dogs and horses. Named as "Vetlen Pouch," this novel drug delivery system provides a fresh approach to delivering concentrated, daily antibiotic treatments directly to infected wounds in canines and equines.
- May 2024: Merck Animal Health announced that it had received approval from the U.S. Department of Agriculture (USDA) for its NOBIVAC NXT Canine Flu H3N2. This innovative product is designed to address the ongoing risk of canine influenza. The product is available in veterinary clinics and hospitals nationwide.
Veterinary Biologics Industry Segmentation
As per the report’s scope, veterinary biologics are products developed to diagnose, manage, or prevent animal diseases. These include vaccines, antibody-based treatments, and diagnostic test kits. Derived from living organisms and biological processes, veterinary biologics function through immunological mechanisms.
The veterinary biologics market is segmented by product type, animal, and distribution channel. By product type, the market has been segmented into vaccines, bacterins, antisera, diagnostic kits, others. Others include growth promoters & allergenic extracts. Based on animal, the market is segmented into companion animals, livestock, and equine. Companion animals have been further segmented into canine, avian, and feline. Livestock segment have been segmented into aquatic, bovine, porcine, ovine, and poultry. By distribution channel, the market covers veterinary clinics, veterinary hospitals, and retail pharmacies. Geographically, the market includes North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. The report details market size and forecasts for 17 countries across these regions, with valuations presented in USD.
By Product Type | Vaccines | ||
Bacterins | |||
Antisera | |||
Diagnostic Kits | |||
Others | |||
By Animal | Companion Animals | ||
Livestock | |||
Equine | |||
By Distribution Channel | Veterinary Clinics | ||
Veterinary Hospitals | |||
Retail Pharmacies | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Veterinary Biologics Market Research FAQs
How big is the Veterinary Biologics Market?
The Veterinary Biologics Market size is expected to reach USD 16.08 billion in 2025 and grow at a CAGR of 6.20% to reach USD 21.71 billion by 2030.
What is the current Veterinary Biologics Market size?
In 2025, the Veterinary Biologics Market size is expected to reach USD 16.08 billion.
Who are the key players in Veterinary Biologics Market?
Boehringer Ingelheim, Ceva, Elanco Animal Health, Hester Biosciences Limited and Meiji Animal Health Co., Ltd are the major companies operating in the Veterinary Biologics Market.
Which is the fastest growing region in Veterinary Biologics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Veterinary Biologics Market?
In 2025, the North America accounts for the largest market share in Veterinary Biologics Market.
What years does this Veterinary Biologics Market cover, and what was the market size in 2024?
In 2024, the Veterinary Biologics Market size was estimated at USD 15.08 billion. The report covers the Veterinary Biologics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Veterinary Biologics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.